Anti-HDAC2 antibody [HDAC2-62]

• IP

Supplier Data

Immunoprecipitation - Anti-HDAC2 antibody [HDAC2-62] (AB12169)

Western Blot using Rabbit anti-HDAC2

Lane 1:

Immunoprecipitation - Anti-HDAC2 antibody [HDAC2-62] (ab12169) at 5 µg

Lane 2:

Immunoprecipitation - Anti-HDAC2 antibody [HDAC2-62] (ab12169) at 2.5 µg

Lane 3:

Negative Control at 5 µg

All lanes:

HeLa whole cell extract

Predicted band size: 55 kDa

false

• WB

Supplier Data

Western blot - Anti-HDAC2 antibody [HDAC2-62] (AB12169)

All lanes:

Western blot - Anti-HDAC2 antibody [HDAC2-62] (ab12169) at 0.5 µg/mL

Lane 1:

Hek293T cell Lysate

Lane 2:

HeLa cell Lysate

Lane 3:

Jurkat cell Lysate

Lane 4:

K562 cell Lysate

Lane 5:

Neuro-2a cell Lysate

Lane 6:

NIH-3T3 cell Lysate

Secondary

All lanes:

Goat Anti-Mouse IgG-Peroxidase

Predicted band size: 55 kDa

false

• WB

AbReview24155****

Western blot - Anti-HDAC2 antibody [HDAC2-62] (AB12169)

All lanes:

Western blot - Anti-HDAC2 antibody [HDAC2-62] (ab12169) at 1/250 dilution

All lanes:

Human glioblastoma cell line at 120 µg

Secondary

All lanes:

HRP-conjugated Goat anti-Mouse at 1/10000 dilution

Predicted band size: 55 kDa

Observed band size: 45 kDa,55 kDa

true

Exposure time: 5min

This image is courtesy of an anonymous abreview.

• WB

CiteAb

Western blot - Anti-HDAC2 antibody [HDAC2-62] (AB12169)

Western Blotting using Anti-HDAC2 antibody [HDAC2-62], ab12169. Publication image from Kook, H. et al., 2015, Nucleic Acids Res, 25765655. Legend direct from paper.

G9a-mediated transcriptional repression of UHRF1 is YY1 dependent. (A) 293T cells were cotransfected with the pGL3-UHRF1 promoter, Flag-G9a and Flag-YY1. Following transfection, cells were grown for 48 h, and cell extracts were assayed for luciferase activity. Expression of the transfected constructs is shown in the immunoblot analysis. (B) pGL3-UHRF1 promoter and the indicated constructs were cotransfected into 293T cells. Twenty-four hours after transfection, 330 nM TSA or 5 mM NIA was added for 24 h, and luciferase activities were subsequently measured. G9a, HDAC1 and HDAC2 expression was confirmed by immunoblot analysis. (C) 293T cells were cotransfected with the pGL3-UHRF1 promoter, Flag-G9a, siCTL RNA and siYY1 RNAs (100 nM). Luciferase activity was measured 48 h after transfection. G9a overexpression and YY1 knockdown by two different siYY1 RNAs are shown in the immunoblot analysis. (A–C) Luciferase activity was normalized to that of β-galactosidase, and the results are presented as means ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001. (D) 293T cells were transfected with siCTL RNA or siYY1 RNAs (100 nM). YY1, G9a, and UHRF1 expression levels were confirmed using real time-PCR and immunoblot analysis. YY1 knockdown by siYY1 RNA is shown in the immunoblot analysis. All results are representative of at least three independent experiments (±SDs). **P < 0.01, ***P < 0.001. (E) 293T cells were transfected with siCTL RNA or siYY1 RNAs. ChIP analysis was performed using anti-G9a, anti-YY1, and anti-H3K9-me2 antibodies, and the results were confirmed by real-time PCR. Recruitment of G9a, YY1 and H3K9-me2 to the UHRF1 promoter and distal region was normalized by input. All results represent at least three independent experiments (±SDs). *P < 0.05, **P < 0.01, ***P < 0.001.

false

• WB

CiteAb

Western blot - Anti-HDAC2 antibody [HDAC2-62] (AB12169)

Western Blotting using Anti-HDAC2 antibody [HDAC2-62], ab12169. Publication image from Sehested, M. et al., 2008, Mol Cancer, 18789133. Legend direct from paper.

Effects of HDAC depletion by siRNA in HeLa cells. A) Down-regulation of HDAC1, 2 or 3 protein after treatment with HDAC1, 2 or 3-targeted siRNA respectively, alone or in combination with other siRNAs at 72 hours post-transfection. Top-row is the appropriate antibody (HDAC1, 2 or 3), while the bottom-row is loading control actin; B) viability as measured by ATP present in culture. For each HDAC knockdown condition, viability was consistently reduced as compared to scrambled siRNA control, in independent measurements (p < 0.01, n = 24); C) The activity of effector caspases 3 and 7 corresponding to apoptotic progression upon HDAC down-regulation or belinostat treatment at increasing concentrations for 24 hours for comparison; D) flow cytometric analysis of DNA content as a function of cell number in control or HDAC combination KD at 48 hours post-transfection, or belinostat treatment at 5.0 µM for 24 hours.

false